Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/jac/dkaa321 http://scihub22266oqcxt.onion/10.1093/jac/dkaa321 32829390!7499641!32829390     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Antimicrob+Chemother 2020 ; 75 (11): 3359-3365 Nephropedia Template TP {{tp|p=32829390|t=2020. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU |pdf=|usr=}}{{32829390}} gab.com Text Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU JO: J Antimicrob Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32829390 #FOAvip BACKGROUND: Remdesivir is a prodrug with in vitro activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Its clinical efficacy in patients with COVID-19 under mechanical ventilation remains to be evaluated. METHODS: This study includes patients under mechanical ventilation with confirmed SARS-CoV-2 infection admitted to the ICU of Pesaro hospital between 29 February and 20 March 2020. During this period, remdesivir was provided on a compassionate use basis. Clinical characteristics and outcome of patients treated with remdesivir were collected retrospectively and compared with those of patients hospitalized in the same time period. RESULTS: A total of 51 patients were considered, of which 25 were treated with remdesivir. The median (IQR) age was 67 (59-75.5) years, 92% were men and symptom onset was 10 (8-12) days before admission to ICU. At baseline, there was no significant difference in demographic characteristics, comorbidities and laboratory values between patients treated and not treated with remdesivir. Median follow-up was 52 (46-57) days. Kaplan-Meier curves showed significantly lower mortality among patients who had been treated with remdesivir (56% versus 92%, P < 0.001). Cox regression analysis showed that the Charlson Comorbidity Index was the only factor that had a significant association with higher mortality (OR 1.184; 95% CI 1.027-1.365; P = 0.020), while the use of remdesivir was associated with better survival (OR 3.506; 95% CI 1.768-6.954; P < 0.001). CONCLUSIONS: In this study the mortality rate of patients with COVID-19 under mechanical ventilation is confirmed to be high. The use of remdesivir was associated with a significant beneficial effect on survival. Twit Text FOAVip Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU ????J Antimicrob Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32829390 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32829390 #FOAvip English Wikipedia <ref>{{Cite pmid|32829390}}</ref> Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU #MMPMID32829390 Pasquini Z; Montalti R; Temperoni C; Canovari B; Mancini M; Tempesta M; Pimpini D; Zallocco N; Barchiesi F J Antimicrob Chemother 2020[Nov]; 75 (11): 3359-3365 PMID32829390show ga BACKGROUND: Remdesivir is a prodrug with in vitro activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Its clinical efficacy in patients with COVID-19 under mechanical ventilation remains to be evaluated. METHODS: This study includes patients under mechanical ventilation with confirmed SARS-CoV-2 infection admitted to the ICU of Pesaro hospital between 29 February and 20 March 2020. During this period, remdesivir was provided on a compassionate use basis. Clinical characteristics and outcome of patients treated with remdesivir were collected retrospectively and compared with those of patients hospitalized in the same time period. RESULTS: A total of 51 patients were considered, of which 25 were treated with remdesivir. The median (IQR) age was 67 (59-75.5) years, 92% were men and symptom onset was 10 (8-12) days before admission to ICU. At baseline, there was no significant difference in demographic characteristics, comorbidities and laboratory values between patients treated and not treated with remdesivir. Median follow-up was 52 (46-57) days. Kaplan-Meier curves showed significantly lower mortality among patients who had been treated with remdesivir (56% versus 92%, P < 0.001). Cox regression analysis showed that the Charlson Comorbidity Index was the only factor that had a significant association with higher mortality (OR 1.184; 95% CI 1.027-1.365; P = 0.020), while the use of remdesivir was associated with better survival (OR 3.506; 95% CI 1.768-6.954; P < 0.001). CONCLUSIONS: In this study the mortality rate of patients with COVID-19 under mechanical ventilation is confirmed to be high. The use of remdesivir was associated with a significant beneficial effect on survival. |*Betacoronavirus[MESH] |*Intensive Care Units/trends[MESH] |Adenosine Monophosphate/*analogs & derivatives/therapeutic use[MESH] |Aged[MESH] |Alanine/*analogs & derivatives/therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19[MESH] |Coronavirus Infections/diagnosis/*mortality/therapy[MESH] |Female[MESH] |Follow-Up Studies[MESH] |Humans[MESH] |Italy/epidemiology[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/*mortality/therapy[MESH] |Respiration, Artificial/*mortality/trends[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH]Effectiveness of remdesivir in patients with COVID-19 under mechanical(epmc).pdf DeepDyve Pubget Overpricing